Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01250808|
Recruitment Status : Available
First Posted : December 1, 2010
Last Update Posted : December 1, 2010
|Condition or disease||Intervention/treatment|
|Multiple Myeloma||Drug: Bortezomib/Dexamethasone/Melphalan|
|Study Type :||Expanded Access|
U.S. FDA Resources
Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.
Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.
Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01250808
|Contact: xiaojun Huang||+86-13701389625|
|Institute of Hematology,Peking University|
|Peking, China, 100044|
|Contact: jin Lu firstname.lastname@example.org|